Validity Diagnostics to show synthetic urine detection tech at SOFT-TIAFT 2026

Validity Diagnostics will present its second-generation urine specimen validity reagents at the SOFT-TIAFT 2026 Joint Meeting in Chicago on Sept. 19-24, 2026, as synthetic and adulterated urine continue to challenge drug-testing programs. The company says its patented tools help labs spot synthetic urine that conventional validity tests miss.

Why it matters: - Synthetic and adulterated urine are making workplace and compliance drug testing less reliable. - Validity Diagnostics says stronger specimen validity testing can help employers, drug courts, probation offices and laboratories protect safety and compliance. - Independent studies cited by the company found its reagents outperformed conventional validity tests on synthetic urine detection.

What happened: - Validity Diagnostics will showcase its second-generation urine specimen validity reagents at the SOFT-TIAFT 2026 Joint Meeting in Chicago, Illinois, on Sept. 19-24, 2026. - The company will highlight the Validity Diagnostics True Essentials Panel, which includes Oxidant History, True Urine LD and True Urine SD reagents. - The products are aimed at Fortune 500 companies, federal and state government employers, federal and state drug courts, probation offices and drug testing laboratories.

The details: - The company says the True Essentials Panel gives laboratories science-backed tools to detect synthetic and/or adulterated urine. - CEO Donna Suggs said workplace urine drug testing depends on the integrity of the urine sample and that VDx products are designed to help labs detect subversion before it affects compliance or workplace safety. - Co-Founder and VP of Sales Garet Rembert said synthetic urine has become a billion-dollar industry built to defeat standard tests. - Rembert said peer-reviewed research from the U.S. military and RTI International found standard validity testing cannot detect synthetic urine. - Validity Diagnostics says its patented technology has identified synthetic urine reliably in multiple independent studies when laboratories use the right tools. - The company points to a 2025 study by Franke et al. from Jena University Hospital in Germany and a 2025 RTI International study in Research Triangle Park, North Carolina. - Those studies found True Urine LD and True Urine SD outperformed conventional validity tests for identifying synthetic urine. - Validity Diagnostics says traditional detection methods are no longer sufficient as synthetic urine products keep evolving. - Validity Diagnostics is based in Branford, Florida. - The company describes itself as an industry leader in laboratory innovation and validity testing for urine drug screening. - The True Essentials Panel is also used before drug testing to help detect synthetic and adulterated samples at laboratories and collection sites. - Validity Diagnostics says it partners nationwide with reference laboratories, hospital laboratories and program administrators. - Contact information in the release lists Ricky P Bateh, PhD, at Validity Diagnostics, +1 904-448-3168.

Between the lines: - The announcement is as much a market warning as a product launch. - Validity Diagnostics is positioning specimen-validity testing as a necessary upgrade because synthetic urine products are evolving faster than conventional screening methods. - The company is also using outside studies to support a broader claim: drug-testing programs may need new detection tools to maintain trust in results.

What's next: - Validity Diagnostics will use the September conference to promote its detection platform to labs and program operators. - The company is likely to push adoption of the True Essentials Panel as synthetic urine use keeps rising. - More laboratories may be pressured to reassess whether standard validity testing is enough for current threat levels.